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Abstract
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative
disorder associated with premutation alleles of the fragile X mental retardation 1 (FMR1) gene.
Approximately 40% of older male premutation carriers, and a smaller proportion of females, are
affected by FXTAS; due to the lower penetrance the characterization of the disorder in females is
much less detailed. Core clinical features of FXTAS include intention tremor, cerebellar gait
ataxia, and frequently parkinsonism, autonomic dysfunction, and cognitive deficits progressing to
dementia in up to 50% of males.
Here, we report the clinical, molecular, and neuropathological findings of eight female
premutation carriers. Significantly, four of these women had dementia; of the four, three had
FXTAS plus dementia. Post mortem examination revealed the presence of intranuclear inclusions
in all eight cases, which included one asymptomatic premutation carrier who died from cancer.
Among the four subjects with dementia, three had sufficient number of cortical amyloid plaques
and neurofibrillary tangles to make Alzheimer’s disease a highly likely cause of dementia and a
fourth case had dementia with cortical Lewy bodies. Dementia appears to be more common than
originally reported in females with FXTAS. Although further studies are required, our observation
suggests that in a portion of FXTAS cases and Alzheimer pathologies a synergistic effect on the
progression of the disease may occurs.
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INTRODUCTION
The FMR1 gene is highly polymorphic for CGG trinucleotide repeats in its 5′ untranslated
region. CGG expansions in the premutation range (55–200 repeats) give rise to the leading
known single-gene cause of primary ovarian insufficiency (Oostra & Willemsen, 2009), and
the late-onset neurodegenerative disorder, FXTAS (Hagerman et al., 2001). FXTAS is
characterized by intention tremor and gait ataxia, with both age-of-onset and severity being
associated with the number of CGG repeats (Tassone et al., 2007, Tassone & Berry-Kravis,
2010). Cerebral atrophy and white matter disease are prominent imaging findings in
individuals with FXTAS (Adams et al., 2007, Adams et al., 2010). White matter MRI
hyperintensities in the middle cerebellar peduncles (i.e., “MCP sign”) represent a major
diagnostic criterion for FXTAS although observable in only 58% of males and 13% of
female carriers (Adams et al., 2007, Brunberg et al., 2002). The pathological hallmark is the
presence of intranuclear inclusions in neurons and astrocytes (Greco et al., 2002), in the
neuroendocrine system (Louis et al., 2006), in the autonomic nervous system, and
myocardial cells (Gokden et al., 2008, Greco et al., 2007, Hunsaker et al., 2011).
The pathogenesis of premutation-associated disorders, particularly FXTAS, is thought to
involve an RNA toxic gain-of-function mechanism, mediated by elevated levels of
premutation length FMR1 mRNA (Allen et al., 2004, Kenneson et al., 2001, Peprah et al.,
2010, Tassone et al., 2000) which has been detected within the intranuclear inclusions
present in the brain (Tassone et al., 2004). Although the role of these inclusions in the
pathogenesis of FXTAS remains unclear, it is likely that they reflect, a much broader
process of cellular sequestration of one or more proteins whose functions are thereby
compromised (Raske & Hagerman, 2009, Sellier et al., 2010).
FXTAS occurs in approximately 40% of carrier males (Jacquemont et al., 2004a) with an
increased likelihood of penetrance with age (Jacquemont et al., 2004b). A reduced FXTAS
penetrance (between 8 and 17%) has been observed in female premutation carriers
(Chonchaiya et al., 2010a, Coffey et al., 2008, Jacquemont et al., 2004b, Rodriguez-
Revenga et al., 2009). This may be primarily due to the protective effect of the normal allele
on the second X chromosome (Berry-Kravis et al., 2005, Jacquemont et al., 2005). Indeed,
female premutation carriers show less frequent clinical and neuropathological features than
male premutation carriers, both with and without FXTAS, but in some cases they may have
symptoms that are as severe as those of their male counterparts (Adams et al., 2007).
FXTAS females have a higher incidence of hypothyroidism, potentially autoimmune thyroid
disease and fibromyalgia, than either age-matched controls or males with FXTAS (Coffey et
al., 2008, Leehey et al., 2011, Rodriguez-Revenga et al., 2009). They also present
hypertension, seizures, and peripheral neuropathy more often than controls (Chonchaiya et
al., 2010b, Coffey et al, 2008, Hamlin et al., 2011). Co-occurrence of multiple sclerosis
(MS) has been described in women carriers (Greco et al., 2008, Zhang et al., 2009). We
have studied eight premutation females and here we report their neuropathological findings,
molecular data, and clinical problems.
MATERIALS AND METHODS
Molecular measures
DNA analysis—Genomic DNA was isolated from peripheral blood leucocytes (5 ml of
whole blood) obtained prior to death, and from post-mortem sections of approximately
500mg of brain tissue using standard methods (Puregene Kit; Gentra Inc.) and under
informed consent according to Institutional Review Board approved protocols. Southern blot
analysis, PCR analysis and calculation of the repeat size for both methods were performed
as described in Tassone et al. (2008). The Activation Ratio (AR), which expresses the
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percent of cells carrying the normal allele on the active X chromosome, was measured using
an Alpha Innotech FluorChem 8800 Image Detection System as previously described
(Tassone et al., 1999).
FMR1 mRNA levels—Total RNA was isolated from peripheral blood leukocytes using
Tempus tubes (Applied Biosystems, Foster City, CA). Reverse transcriptase reactions and
quantifications of FMR1 mRNA were performed as described in Tassone et al. (2000).
Pathology
Formalin-fixed brain tissue for all cases was processed for paraffin sections, and histological
and immunohistological staining in standard fashion as previous reported (Greco et al.,
2006, Greco et al., 2002). Tissue blocks of frontal cortex and hippocampus were obtained
from five age matched control female subjects (age range 60–76 years). Tissues were
selected to be the same across all cases to facilitate comparisons among experimental cases.
Control cases were obtained from pathology files at Department of Pathology at University
of California, Davis according to UC Davis approved IRB protocol.
Evaluation of AD neuropathology
We evaluated the AD neuropathology, including the Braak and Braak stage and the CERAD
plaque score, using the Diagnostic Criteria for the Neuropathological Assessment of
Alzheimer’s Disease, following the recommendation by the National Institute on Aging and
Reagan Institute Working Group (NIA-Reagan criteria) (1997).
Quantitative analysis of intranuclear inclusion number
Percentages of intranuclear inclusions in neurons and astrocytes were determined for frontal
cortex, hippocampus, and middle superior temporal gyrus using protocols previously
described (Greco et al., 2006, Greco et al., 2002, Greco et al., 2008). Tissue from blocks of
frontal cortex and hippocampus were obtained for 8 female cases and middle superior
temporal gyrus was obtained for 7 of these cases. Quantifications were compared to
previously reported female control cases from Greco et al. (2006). These control cases
matched the age range of the present female cases, and were free of gross neuropathological
features or histological artifacts.
Brain tissues were blocked and sectioned in the same orientation to facilitate histological
analysis. Tissues were paraffin embedded, sectioned at 10 μm, and stained with hematoxylin
and eosin (H&E). Three sections separated by 50 μm were used for unbiased cell counting.
To estimate the number of intranuclear inclusions in females with the fragile X premutation
both with and without FXTAS, regions of interest were outlined within the frontal cortex,
superior medial temporal gyrus, and hippocampus, using the StereoInvestigator (v 8.0, MBI,
Inc.; Williston, TN) software package and a Nikon E600 Eclipse microscope at 400x
magnification. All parameters explicitly replicated those reported by Greco et al. (2006)
quantifying inclusions presence in male FXTAS cases to facilitate comparison between the
results of that study and the present report. To reduce bias in our samples, standard sections
were taken from all control cases and premutation cases to allow direct comparisons among
cases. Unbiased sampling techniques were used to collect and define a systematic, random
sampling of the tissue to ensure an unbiased estimation of inclusion number, but no rigorous
stereology was carried out in the present study and we are reporting the actual number of
items counted, not estimated values provided by the software. Briefly, these techniques
involved tracing the regions of interest at 40X magnification by an experimenter blinded to
the identity of each case (i.e., slide blinded). Once the region of interest was traced, the
software placed a regular grid of sampling frames across the region of interest using a
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randomized starting point. The size of the counting frame and spacing of the grids were the
same as reported in Greco et al. (2006). This way, there was a rigorous, systematic sampling
of the area contained within the region of interest, but the experimenter did not have control
over precisely which areas of the region of interest were sampled. Counting of cells
containing intranuclear inclusions was performed at 400X. Cell identification within the
regions of interest was based on standard morphological criteria as previously described
(Greco et al., 2006, Greco et al., 2002). The numbers obtained from these cell counts were
converted to ratios (# of cell type with inclusions/total # of cell type counted).
RESULTS
Clinical Histories
Key clinical features and molecular characteristics of the eight cases included in this study
are presented in Table 1.
Case 1—Case 1 was an asymptomatic premutation carrier who had no neurological,
behavioral, or cognitive symptoms by history. She had a 30 CGG repeat normal allele and
70 CGG repeat premutation allele with an activation ratio (AR) = 0.8. Her FMR1 mRNA
levels were 1.31 (+/− 0.11) times normal. At age 40, she experienced an episode of Bell’s
palsy. She had dry eyes resulting from cataract surgery in her early 70’s. At age 73, she
developed uterine cancer and had a hysterectomy, followed by radiation treatment and
chemotherapy. She died of uterine cancer at age 76, after a downhill course involving
weakness and cognitive decline terminally.
Case 2—Case 2 experienced her first symptoms at the age of 56 years, presenting with
expressive and receptive aphasia. The aphasia was not acute and there was no indication of a
stroke. The detailed work up ruled out vascular infectious or inflammatory etiology. She had
a normal and a premutation allele of 30 and 80 CGG repeats and an AR = 0.3. Her FMR1
mRNA levels were 6.06 (+/− 0.16) times normal. For this case, transcript levels were
measured using frontal cortex as blood samples were not available. She subsequently
developed hyperphagia, incontinence, and hallucinations. A positron emission tomography
(PET) scan at age 61 showed hypoperfusion in left greater than right temporal lobes, and a
brain MRI revealed mild cortical atrophy. Later, she experienced sudden falls and then
swallowing difficulties. She died at 66 years of age after a progressive neurological and
cognitive decline, and dementia.
Case 3—Case 3 had a history of mild FXTAS and was initially reported in Hagerman et al.
(2004). She had a normal and a premutation allele of 29 and 87 CGG repeats, respectively,
and an AR = 0.53. Her FMR1 mRNA level was 2.31 (+/− 0.17) times normal. She was a
social worker who had 2 children with FXS. She had a long history of anxiety and she
developed depression at age 75, which was treated with fluoxetine. Mild ataxia began at age
79, necessitating use of a cane. She developed an intention tremor and extremity weakness
at age 82 years. She required a pacemaker in her 80s for cardiac arrhythmias. She fell and
fractured her left hip at age 84. She did not have any significant cognitive deficits except for
impaired memory a few months prior to death. She died at age 85 from complications
related to gastrointestinal surgery for ileus.
Case 4—Case 4 was originally reported in 2008 (Greco et al., 2008), emphasizing the co-
occurence diagnosis of FXTAS and multiple sclerosis (MS). The FMR1 alleles had 36 and
75 CGG repeats in size with an AR = 0.44. Her FMR1 mRNA levels were 2.80 (+/− 0.12)
times normal. She died of MS at age 52, having been found to be a carrier just 2 weeks
before her death after her daughter was diagnosed as a carrier by her OB/GYN physician on
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the basis of ovarian dysfunction. She developed neurological symptoms at age 32 years,
with numbness in her arm and optic neuritis. By age 38 she had developed gait ataxia and
loss of dexterity in the right hand. Her MRI demonstrated diffuse atrophy and multiple foci
of increased T2 signal intensity in the periventricular and cerebellar white matter including
the middle cerebellar peduncles (MCP sign). She was diagnosed with MS and treated with
several regimens including methotrexate, but her symptoms gradually progressed. She
developed an upper extremity intention tremor, progressive dysarthria, lower extremity
numbness, and eventually spastic paraparesis and cognitive decline. She was unable to
swallow and she became incontinent and bedridden before her death at age 52.
Case 5—Case 5 had normal and premutation alleles of 30 and 65 CGG repeats,
respectively, and an AR = 0.28. No FMR1 mRNA levels are available. Her medical history
was unremarkable beside AD later in life. Her psychiatric history included anxiety and
depression. At 73 years of age she was diagnosed with AD by her neurologist and started
taking donepezil. At age 77 years, she was placed in an assisted living setting and a year
later she moved to an AD nursing home unit after a fall resulting in a broken ankle. She was
unsteady in her walking and had tremor before death. Her downhill course was rapid. She
did not have an MRI. She died as a result of AD at age 80 as result of AD.
Case 6—Case 6 was a premutation carrier; the mother of two sons with FXS, who died of
FXTAS at age 65. This case has been previously described by Yachnis and colleagues
(Yachnis et al., 2010). Her FMR1 mRNA levels and number of CGG repeats are unknown
as only fixed tissues were available and results of previous genetic testing were unknown.
She had a history of fibromyalgia symptoms starting at age 40 years with pain in her
extremities, she also had hypothyroidism, and menopause at age 45. At age 58 she
developed handwriting difficulties because of an intention tremor. At age 59 years her
tremor worsened and involved hands and arms bilaterally. Her left hand would spasm and
would close with increased tone. She also developed bladder incontinence and restless leg
syndrome between age 59 and 60. She subsequently became physically weaker, with
cognitive decline beginning at age 60 years, leading to a diagnosis of dementia, which was
said to be rapidly progressive after age 60 (Yachnis et al., 2010). Her cognitive decline was
characterized by getting lost, poor judgment and hygiene, eventually she lost the ability to
converse. She required a walker at age 61 years due to ataxia, began using a wheelchair
regularly at age 62, and by 63 years of age she was bedridden. Her MRI demonstrated white
matter disease. She was hospitalized with aspiration pneumonia and died with respiratory
failure.
Case 7—Case 7 died at age 84 years from FXTAS. She had two alleles, of 27 and 59 CGG
repeats, and an AR = 0.63. Her FMR1 mRNA levels were 1.83 (+/− 0.12) times normal. She
had two daughters and one son with the premutation, and three grandchildren with FXS. She
was well until age 67 when she developed hypertension. She developed breast cancer in her
70s and was treated with a lumpectomy and radiation. She subsequently developed a hand
tremor at age 78 with deteriorating handwriting; she was diagnosed with Parkinson’s disease
and was treated with carbidopa/levodopa. Ataxia began at age 80 with frequent falling and
cognitive decline that necessitated 24-hour care. By age 82 she did not recognize family
members and spoke very little. She was diagnosed with dementia with Lewy Bodies (DLB);
treatment with donepezil and memantine showed some clinical benefit. She gradually
became weaker and was unable to walk independently after age 82 years; she then used a
wheelchair consistently. On examination at age 83 she had an intention tremor, global
weakness, and severe neuropathy with edema and absent vibration and pin prick sensation in
her lower extremities. Her MRI demonstrated severe white matter disease in the pons,
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caudate, putamen, and thalamus, in addition to global cerebral atrophy. There were ischemic
changes in her basal ganglia with iron deposits in her cerebellar dentate nuclei.
Case 8—Case 8 was originally reported in 2004 as the fifth case of the original case series
of women with FXTAS (Hagerman et al., 2004). She had alleles of 30 CGG and 78 CGG
repeats, and an AR = 0.21. Her FMR1 mRNA levels were 2.6 (+/− 0.04) times normal. She
developed episodes of lightheadedness, unsteady gait, and frequent falls at age 71 years. She
also developed an intention tremor of the hand that improved first with propranolol and then
more markedly with primidone. Subsequently she developed numbness in her lower
extremities. At age 74 she had bradykinesia, dystonia of the neck muscles, and upper
extremity rigidity in addition to an intention tremor and ataxia. Her symptoms gradually
worsened and she died of respiratory failure at the age of 79.
Gross and microscopic findings
Case 1—Fresh brain weight was 1231 g. Gross examination of the brain showed no
pathological changes. Comprehensive microscopic examination of the brain identified
intranuclear inclusions in neurons and astrocytes (Figure 1D), and mild vascular hyalinosis
of white matter. Neither neurofibrillary tangles (NFTs) changes or plaque formation was
seen on the modified Bielschowsky stain (Braak and CERAD stage 0).
Case 2—Total brain weight (fixed) was 1140 g. Gross examination showed global atrophy,
and diffuse cerebrovascular atherosclerosis. Microscopic examination of the brain showed
intranuclear inclusions as established for the histological diagnosis of FXTAS (Figure
1A,B). Loss of cortical neurons, occasional senile plaques, granulovacuolar degeneration
(GVD), and NFTs were identified in frontal and temporal cortices. The hippocampus
showed prominent formation of NFTs, GVD, and senile plaques in CA1. Bielschowsky stain
showed abundant plaques and NFTs conforming to Braak and Braak Stage V–VI and
CERAD plaque assessment as “frequent”.
Case 3—Fresh brain weight was 980 g. Gross examination showed cerebral edema, and
small, scattered, atheromatous plaques in the circle of Willis. Neurons and astrocytes
demonstrated intranuclear inclusions throughout the central nervous system. There was
patchy pallor of subcortical, deep, and periventricular white matter evident on both H&E
and myelin stains, and patchy myelin pallor involved arcuate fibers in a patchy distribution.
Bielschowsky stain showed few NFTs, plaques and GVD in hippocampus, and only rare
plaques in cortical sections, consistent with Braak and Braak Stage I–II and a “sparse”
CERAD plaque score.
Case 4—A detailed neuropathological description was presented previously in Greco et al.
(2008). In brief, gross examination showed cortical atrophy and scattered, discrete plaques
of demyelination throughout the brain. Histological evaluation identified characteristic
features seen with multiple sclerosis, and the intranuclear inclusions in neurons and
astrocytes described in FXTAS. Bielschowsky stain showed no NFTs or plaque formation.
Case 5—Brain weight was unavailable. Gross examination of the brain showed moderate
frontal lobe atrophy, ventricular enlargement, and cerebrovascular atherosclerosis. Gray
matter was thinned to 3 mm in all lobes. Intranuclear inclusions were present in neurons and
astrocytes. Histological features seen corresponded to Braak and Braak Stage V–VI. The
CERAD plaque count showed “frequent density” of neuritic and cored plaques.
Case 6—The brain weighed 1040 gm., and showed mild cerebrovascular atherosclerosis.
Mild cortical atrophy was present, favoring frontal, insular, and temporal cortices, with
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severe hippocampal atrophy. Neurons and astrocytes demonstrated intranuclear inclusions
throughout the central nervous system (Figure 1C). Marked ventriculomegaly was seen, and
some regions of white matter appeared almost translucent. Bielschowsky stain identified
AD-like changes that corresponded to Braak and Braak Stage V–VI. According to CERAD
criteria, plaques were “frequent” in density.
Case 7—Brain weight was unavailable. There was mild fronto-parietal cortical atrophy
without ventriculomegaly, and mild spotty atherosclerosis in the Circle of Willis.
Bielschowsky stain showed AD-like pathology that corresponded to Braak and Braak Stage
I–II. Lewy bodies were seen in cortical areas and brainstem dopaminergic neurons.
Case 8—Brain weight was 930 gm., and showed moderate ventriculomegaly on cut
section. The hippocampus was markedly atrophied. Histologic features as established for a
post-mortem histological diagnosis of FXTAS were present. Bielschowsky stain identified
AD-like pathological features corresponding to Braak and Braak Stage V–VI. “Moderate”
numbers of plaques were present as per CERAD criteria. Severe arteriosclerosis was
prominent in gray and white matter of frontal and temporal cortices.
Quantitative analysis of intranuclear inclusion number
The number of neurons and astrocytes with intranuclear inclusions (actual cell counts and
percentages) are presented in Table 2 for frontal cortex, superior middle temporal gyrus, and
hippocampus. No inclusions in neurons or astrocytes were observed for any of the similarly
aged control subjects counted (n=6), and no inclusions were observed in the cytoplasm of
neural cells in tissues from control or premutation cases. Intriguingly, the percentages of
neurons and astrocytes with intranuclear inclusions were roughly equivalent in the female
FXTAS cases, across all three areas evaluated (% +/− SEM) 9.03 +/− 1.62% neurons vs.
8.21 +/− 0.96% of astrocytes), which is in contrast to the findings previously reported in
males (Greco et al., 2006). Importantly, there were no differences for number of cells
counted among the experimental cases and control tissues counted using the same
techniques.
DISCUSSION
The two most significant findings of this study are the presence of intranuclear inclusions in
all cases and a high number of them presenting with AD neuropathological changes. Female
carriers of the fragile X premutation, both with and without a FXTAS clinical diagnosis,
show similar numbers of intranuclear inclusions in neurons in the cortex and hippocampus
as do men with FXTAS. The number of intranuclear inclusions in astrocytes, however, was
greatly reduced in female carriers relative to the levels observed in male FXTAS cases
(Greco et al., 2006, Greco et al., 2002). Additionally, we found evidence of intranuclear
inclusions in all cases, even though one woman (Case 1) was asymptomatic. To our
knowledge this is the first report of intranuclear inclusions in a fragile X premutation female
carrier that showed no clinical symptoms associated with FXTAS. There also appeared to be
little to no contribution of co-morbid disorders to the number of intranuclear inclusions in
any of the female premutation and FXTAS cases. Two other striking findings were the high
number of women carriers with dementia (Cases 2, 5, 6, and 7), much higher than expected
given previous reports, and the high level of AD-type plaque and tangle pathologies (Cases
2, 5, 6, and 8), with or without corresponding clinical AD signs.
Importantly, we have demonstrated that although the presence of intranuclear inclusions is
considered a primary diagnostic criterion for FXTAS (Hagerman et al., 2004, Jacquemont et
al., 2003), the presence of intranuclear inclusions may be necessary but not sufficient to lead
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to FXTAS symptoms. Two of the cases presented here did not have a FXTAS diagnosis at
the time of death. Case 1 died of a uterine cancer for which she received radiation and
chemotherapy. It is possible that the CNS trauma of the cancer treatment could have
precipitated the formation of inclusions and FXTAS as was previously described in ODwyer
et al. (2008) where chemotherapy lead to CNS white matter disease and clinical symptoms
of FXTAS. However, the presence of the fragile X premutation appears to be sufficient for
the presence of intranuclear inclusions, even when there are relatively normal levels of
FMR1 mRNA, as demonstrated by the findings in Case 1. It is possible that genetic and
environmental factors, including the genetic background and a favorable AR, may have
played a role in the absence of FXTAS symptoms in Case 1. A high AR (0.8) was in fact
measured in Case 1 in both peripheral blood leukocytes and also in brain tissue. Case 5 had
a history of anxiety and depression, which are common in carriers (Bourgeois et al., 2009;
Bourgeois et al., 2011; Roberts et al., 2009) and then presented with dementia with
subsequent decline that included falling. Dementia has occasionally been a presenting sign
of FXTAS and in Sevin et al. (2009) cognitive decline was more common in carriers
compared to controls even in those without tremor and ataxia. Our cases demonstrate that
the inclusions of FXTAS are more common than previously thought even in female carriers
without classical symptoms of FXTAS.
Interestingly, cases 2, 5, 6, and 7 presented with dementia, which has only rarely been
described in women with FXTAS. Only five women with FXTAS and dementia have been
reported to date (Al-Hint et al., 2007; Karmon & Gadoth, 2008; Rodriguez-Revenga et al.,
2009; Yachnis et al., 2010). Thus, the present case series greatly enriches the existing
literature with these additional three cases (cases 2, 6, and 7). In three of the women we
described (Cases 2, 5, and 6), there is a high likelihood that dementia was due to AD lesions
according to the Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s
Disease recommended by the National Institute on Aging and Reagan Institute Working
Group (1997). The etiology of dementia in Case 7, who only had low levels of AD lesions,
is not clear but the presence of Lewy bodies suggests a diagnosis of DLB (McKeith, 2006)
or PD dementia. We have also seen the occurrence of FXTAS inclusions and Lewy bodies
in one man with FXTAS (Greco et al., 2002). It is, in fact, possible that individuals with
FXTAS who developed cognitive changes may get diagnosed as having AD, PD, or DLB,
since dementia in FXTAS has an interesting cortical-subcortical picture which may partially
mimic other neurodegenerative dementias (Seritan et al., 2008). Dementia associated with
FXTAS has a characteristic profile different than other dementias, even though deficit
severity may be of the order of the deficits encountered in AD (Bacalman et al., 2006,
Seritan et al., 2008). Patients in more advanced stages of FXTAS (Gane et al., 2010)
develop both cortical (apraxia, memory recall, visuospatial skills impairment) and
subcortical (memory retrieval, bradyphrenia, latency of speech, mood and personality
changes) cognitive deficits, in conjunction with the movement disorders described (ataxia,
tremor, bradykinesia, parkinsonian features). Although aphasia may be present, language is
typically spared early in FXTAS (Grigsby et al., 2007). Executive dysfunction is the most
prominent deficit (Grigsby et al., 2008, Grigsby et al., 2007), it may occur prior to
development of a full dementia and appears to mediate other cognitive deficits (Brega et al.,
2008). These women described with FXTAS and neurocognitive changes presented with a
variety of clinical features, making a specific dementia diagnosis difficult. It is not clear
whether all the cognitively impaired women described here had FXTAS dementia, since one
was also diagnosed with AD and another, with DLB. However, co-occurrence of FXTAS
with other neurological disorders may exacerbate symptom severity and contribute to a
faster decline.
Although further studies using a larger series are required, we hypothesize that a previously
unrecognized association may exist between the FMR1 premutation and AD pathology.
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There may be a synergy of having both disorders because both have mitochondrial
dysfunction and both have oxidative stress and these problems could be amplified when they
occur together (Ross Inta et al., 2010; Napoli et al., 2011; Ye et al., 2011; Karbowski and
Neutzner, 2012). However, this association could be independent of the development of
FXTAS, as Case 5 developed AD without FXTAS. Because of the high frequency of female
premutation carriers in the general population (1:110–259 females), the contribution of
aberrant FMRP (FMR1 protein) metabolism to the development of AD should be evaluated.
FMRP controls amyloid precursor protein (APP) through inhibition (Darnell et al., 2011)
and FMRP may be somewhat lower in the brains of carriers (Handa et al., 2005, Qin et al.,
2011) and if so APP levels may be higher in premutation carriers, as reported in Handa et al.
(2005), possibly predisposing them to AD.
In summary, dementia is more common than had been previously observed in female
premutation carriers, and the co-occurrence of AD-associated NFTs and plaques and
FXTAS neuropathologic changes in this small series is a striking finding. Larger studies will
be necessary to further substantiate this finding. The essential role of the premutation (even
with normal FMR1 mRNA levels) in the inclusion formation is a cardinal finding, which
will also need to be further explored in subsequent studies.
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Figure 1.
A. Intranuclear inclusions in pyramidal cells in CA3b of Case 2. B. Intranuclear inclusions
in granule cells of the medial blade of the dentate gyrus of Case 2. C. Intranuclear infusions
in pyramidal cells and neurons in the hilus of case 6. c. Inset, intranuclear inclusion in
neuron and astrocyte in the white matter adjacent to layer VI of the frontal cortex of Case 6.
D. Intranuclear inclusion in an astrocye in layer II if the frontal cortex of Case 1. d. Inset,
granule cell from layer IV of the frontal cortex in Case 1. All plates are at 1000X
magnification. Scale bar = 50μm.
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